Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 9/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5284313 | 0.82 | HDAC2 (0.65) | HDAC2HDAC8HDAC6SMN1; SMN2ALDH1A1 | |
| SCHEMBL5284317 | 0.82 | HDAC2 (0.65) | HDAC2HDAC8HDAC6SMN1; SMN2ALDH1A1 | |
| SCHEMBL5278026 | 0.80 | HDAC2 (0.62) | HDAC2HDAC8HDAC6SMN1; SMN2ALDH1A1 | |
| SCHEMBL6037999 | 0.80 | HDAC2 (0.62) | HDAC2HDAC8HDAC6SMN1; SMN2ALDH1A1 | |
| SCHEMBL5278032 | 0.80 | HDAC2 (0.62) | HDAC2HDAC8HDAC6SMN1; SMN2ALDH1A1 | |
| SCHEMBL6037998 | 0.80 | HDAC2 (0.62) | HDAC2HDAC8HDAC6SMN1; SMN2ALDH1A1 | |
| SCHEMBL5579685 | 0.74 | HDAC2 (0.80) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5579684 | 0.74 | HDAC2 (0.80) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5078965 | 0.74 | HDAC2 (0.76) | HDAC2HDAC8HDAC6 | |
| SCHEMBL5078964 | 0.74 | HDAC2 (0.76) | HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | HDAC2 5/4885HDAC8 11/4885HDAC6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.